, /PRNewswire/ -- , a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), has engaged GATC advisor Dr. to oversee FDA Investigative New Drug (IND)-enabling studies to advance GATC compounds to human clinical trials. Dr.
Beyer has significant experience in obtaining INDs and the regulatory pathway in the addiction space and he will augment the company's current research to secure FDA approval to enter phase one clinical trials for this AI-generated OUD asset. Dr. Beyer has served as a member of GATC's Board of Advisors since and is a pharmaceutical executive with an expertise in addiction medicine and more than two decades of experience in the biopharmaceutical industry.
"The preclinical data from GATC's OUD candidate demonstrates the compound could be a powerful solution to turn around this deady epidemic," said Dr. Beyer. "Through its AI platform, GATC has uncovered multiple targets along with a novel compound that have tested extremely well for effectiveness and safety.
I am excited to consult with the team to advance this promising set of medications toward human trials," added Dr. Beyer. "Chad has served on our advisory board as a valued expert in addiction medicine, with a substantial history in achieving the types of regulatory milestones we are seeking with our OUD asset," said , Chief Science Officer at GATC.
"Buoyed by the results of our recent animal trials on this drug candidate at , we are ready to leverage Chad's.
